JP2024541048A - 抗cd122抗体、抗cd132抗体、及び関連する二重特異性結合性タンパク質 - Google Patents

抗cd122抗体、抗cd132抗体、及び関連する二重特異性結合性タンパク質 Download PDF

Info

Publication number
JP2024541048A
JP2024541048A JP2024525790A JP2024525790A JP2024541048A JP 2024541048 A JP2024541048 A JP 2024541048A JP 2024525790 A JP2024525790 A JP 2024525790A JP 2024525790 A JP2024525790 A JP 2024525790A JP 2024541048 A JP2024541048 A JP 2024541048A
Authority
JP
Japan
Prior art keywords
seq
cdr
sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541048A5 (cg-RX-API-DMAC7.html
Inventor
ゴン,シーヨン
フアン,リニ
ウー,チェンビン
ウー,ダンキン
ウー,シュアン
ザン,ルイ
Original Assignee
シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド filed Critical シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド
Publication of JP2024541048A publication Critical patent/JP2024541048A/ja
Publication of JP2024541048A5 publication Critical patent/JP2024541048A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024525790A 2021-11-02 2022-10-24 抗cd122抗体、抗cd132抗体、及び関連する二重特異性結合性タンパク質 Pending JP2024541048A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/128208 2021-11-02
CN2021128208 2021-11-02
PCT/CN2022/127036 WO2023078113A1 (en) 2021-11-02 2022-10-24 Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins

Publications (2)

Publication Number Publication Date
JP2024541048A true JP2024541048A (ja) 2024-11-06
JP2024541048A5 JP2024541048A5 (cg-RX-API-DMAC7.html) 2025-10-30

Family

ID=86240641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525790A Pending JP2024541048A (ja) 2021-11-02 2022-10-24 抗cd122抗体、抗cd132抗体、及び関連する二重特異性結合性タンパク質

Country Status (7)

Country Link
US (1) US20250002594A1 (cg-RX-API-DMAC7.html)
EP (1) EP4426742A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024541048A (cg-RX-API-DMAC7.html)
CN (1) CN118251416A (cg-RX-API-DMAC7.html)
CA (1) CA3236138A1 (cg-RX-API-DMAC7.html)
TW (1) TW202334219A (cg-RX-API-DMAC7.html)
WO (1) WO2023078113A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN116789828B (zh) * 2023-05-31 2023-11-17 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种抗cd132的单克隆抗体及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
CN118909123B (zh) * 2024-01-19 2025-09-05 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 人源化抗人cd132单克隆抗体及其应用
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2026033139A1 (en) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
CN122255271A (zh) * 2024-12-20 2026-06-23 三生国健药业(上海)股份有限公司 抗cd122抗体及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560994B1 (en) * 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
PT3328894T (pt) * 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
CN111954680B (zh) * 2017-11-10 2024-03-15 新加坡科技研究局 IL2Rβ/共同γ链抗体
WO2020094834A1 (en) * 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
CN113474370B (zh) * 2019-02-01 2025-04-01 瑞泽恩制药公司 抗IL2受体γ抗原结合蛋白

Also Published As

Publication number Publication date
CA3236138A1 (en) 2023-05-11
WO2023078113A1 (en) 2023-05-11
TW202334219A (zh) 2023-09-01
CN118251416A (zh) 2024-06-25
EP4426742A1 (en) 2024-09-11
EP4426742A4 (en) 2025-12-24
US20250002594A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
WO2023078113A1 (en) Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins
JP7781859B2 (ja) 抗ror1抗体及び関連の二重特異性結合タンパク質
JP7562528B2 (ja) 抗体及びその用途
JP7847630B2 (ja) Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
US20240425593A1 (en) Anti-pd-1 antibody and use thereof
WO2022258015A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
WO2025168114A1 (en) Multifunctional nk cell engager
EP4613767A1 (en) Bispecific antibody for glypican-3 and use thereof
RU2844869C1 (ru) Антитела против ror1 и родственные биспецифичные связывающие белки
HK40061499A (en) Anti-ror1 antibodies
TW202509067A (zh) 抗cd25抗體及其用途
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240501

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251022